Gene therapy, stress haematopoiesis and the risk of malignancy

基因治疗、应激造血和恶性肿瘤风险

• 批准号: nhmrc : 632657
• 负责人: A/Pr Matthew Mccormack
• 金额: $ 41.17万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/gene-therapy-stress-risk-malignancy/96167
• 关键词: Gene; therapy; stress; haematopoiesis; risk

The immense potential of gene therapy has been confirmed by the successful treatment of immune deficiencies disorders. A key issue that has emerged however is the need to avoid potentially cancer-causing genetic damage to cells undergoing repair. Some of this risk can be linked to the gene repair technology used, but we have identified and propose to investigate another potentially important mechanism involving the unusually high levels of replication imposed on cells during disease correction.

基因疗法的巨大潜力已被免疫缺陷疾病的成功治疗所证实。然而，出现的一个关键问题是，需要避免对正在修复的细胞造成潜在的致癌基因损伤。其中一些风险可能与所使用的基因修复技术有关，但我们已经确定并建议调查另一个潜在的重要机制，涉及在疾病纠正期间施加在细胞上的异常高水平的复制。